Skip to main content
. 2022 Jun 21;6(3):100043. doi: 10.1016/j.shj.2022.100043

Table 1.

Demographic characteristics, clinical presentations, echocardiographic data, and procedural safety and quality measures of the studied patients

Characteristics N = 16
Demographic characteristics
 Age (y) 55.75 ± 16.69
 Male gender 8 (50%)
 Weight (Kg) 69.13 ± 9.40
 Height (m) 1.59 ± 0.09
 BSA (m2) 1.71 ± 0.17
 Medical comorbidities
 Hypertension 8 (50%)
 Diabetes mellitus II 4 (25%)
 Chronic kidney disease 5 (31.25%)
 Previous cancer/chemotherapy 2 (12.5%)
 Liver cirrhosis 2 (12.5%)
 Bronchial asthma 1 (6.25%)
 Peripheral vascular disease 2 (12.5%)
 Hypothyroidism 3 (18.75%)
 Original diagnosis
 CAD 4 (25%)
 DCM 7 (43.75%)
 Myxomatous MV 2 (12.5%)
 AV lesions 2 (12.5%)
 No cardiac history 1 (6.25%)
 Previous interventions
 CABG 3 (18.75%)
 Valve surgery 5 (31.25%)
 MitraClip devices 2 (12.5%)
 No previous interventions 6 (37.5%)
 Previous rings/clips in MV position
 No 12 (75%)
 Rings 2 (12.5%)
 Clips 2 (12.5%)
 Time since last intervention (mo) 22.83 ± 20.44
 Previous cardiac medications
 Yes 15 (93.75%)
 No 1 (6.25%)
 STS score (%) 12.35 ± 8.62
Clinical presentations
 NYHA-FC
 III 10 (62.5%)
 IV 6 (37.5%)
 HF hospitalization within the last 12 mo 2.86 ± 1.07
 Auscultation
 Pansystolic murmur 15 (93.75%)
 Midsystolic murmur 1 (6.25%)
Echocardiographic data
 Etiology and site of MR MVL perforations: 9 (56.25%)
 Iatrogenic AML perforation 4 (25%)
 Ischemic AML perforation 2 (12.5%)
 Spontaneously ruptured aneurysm with a perforation in AML 1 (6.25%)
 Postinfective para-ring perforation/leak 2 (12.5%)
 Post-MitraClip residual MR jets 7 (43.75%)
 Commissural residual MR 3 (18.75%)
 Inter-MitraClip residual MR 4 (25%)
 MR severity
 Moderate (II) 0 (0%)
 Severe (III) 16 (100%)
 Perforation/jet diameters (mm) 5.75 ± 1.67 × 6.5 ± 1.93
 3D-VCA (EROA) (cm2) 0.54 ± 0.14
 MV Pg (mmHg) 3.42 ± 0.84
Procedural safety and quality measures
 General anesthesia 16 (100%)
 Septal puncture 16 (100%)
 Apical puncture 3 (18.75%)
 Invasive LAP (mmHg) 44.38 ± 6.26
 Crossing approach
 Antegrade transvenous/transeptal 7 (43.75%)
 Retrograde transaortic 7 (43.75%)
 Retrograde transapical 2 (12.5%)
 Crossing catheters
 JR 1 (6.25%)
 PG 1 (6.25%)
 IM 2 (12.5%)
 MP 5 (31.25%)
 Agilis 7 (43.75%)
 Arteriovenous loop
 Yes 6 (37.5%)
 No 10 (62.5%)
 Deployment approach
 Antegrade transvenous/transeptal 13 (81.25%)
 Retrograde transapical 3 (18.75%)
 Device type
 Amplatzer ASO 10 (62.5%)
 Amplatzer VP-II 6 (37.5%)
 Number of devices used
 One 15 (93.75%)
 Two 1 (6.25%)
 Procedure type
 Elective 9 (56.25%)
 Urgent 5 (31.25%)
 Emergency/salvage 2 (12.5%)
 Procedural time (min) 55.13 ± 16.24
 Fluoroscopy time (min) 16.25 ± 4.03
 Contrast (mL) 33.75 ± 10.94
 Radiation dose (μGym2) 16.25 ± 4.41
 Technical success
 Yes 16 (100%)
 No 0 (0%)
 Complete closure
 Yes 15 (93.75%)
 Residual shunt 1 (6.25%)
 Procedural complications
 No 13 (81.25%)
 Access site complications 1 (6.25%)
 Arrhythmia/CHB/new pacemaker 2 (12.5%)
 Conversion to open heart surgery
 Yes 0 (0%)
 No 16 (100%)
 Procedure-related mortality
 Yes 0 (0%)
 No 16 (100%)

3D, 3-dimensional; AML, anterior mitral leaflet; ASO, atrial septal occluder; AV, aortic valve; BSA, body surface area; CABG, coronary artery bypass graft; CAD, coronary artery disease; CHB, complete heart block; DCM, dilated cardiomyopathy; EROA, effective regurgitant orifice area; HF, heart failure; IM, internal mammary; JR, Judkin right; LAP, left atrial pressure; MP, multipurpose; MR, mitral regurgitation; MV, mitral valve; MVL, mitral valve leaflet; NYHA-FC, New York Heart Association Functional Class; PG, pigtail; Pg, pressure gradient; STS, Society of Thoracic Surgeons; VCA, vena contracta area; VP, vascular plug.